Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q3 FY26 results · Oct–Dec 2025
Tatva Chintan Pharma Chem reported revenue from operations of ₹131.33 crore (up 52.9% from Q3 FY25) and net profit of ₹15.16 crore (up 10889.1% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 131.33 | 85.90 | +52.9% | 123.52 | +6.3% |
| Other income | 1.73 | 0.04 | 39x | 1.01 | +72.0% |
| Total income | 133.07 | 85.94 | +54.8% | 124.52 | +6.9% |
| Profit before tax | 17.66 | (0.23) | Turned profit | 13.66 | +29.2% |
| Net profit for the period | 15.16 | 0.14 | 110x | 9.92 | +52.9% |
| EPS, basic (₹) | 6.49 | 0.06 | 108x | 4.24 | +53.1% |
| Net margin (%) | 11.5 | 0.2 | 8.0 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 138.59 | 84.00 | +65.0% | 115.86 | +19.6% |
| Other income | 1.73 | 0.04 | 43x | 0.79 | +118.4% |
| Total income | 140.32 | 84.04 | +67.0% | 116.66 | +20.3% |
| Profit before tax | 18.79 | (1.65) | Turned profit | 12.34 | +52.2% |
| Net profit for the period | 15.98 | (1.17) | Turned profit | 8.94 | +78.8% |
| EPS, basic (₹) | 6.84 | (0.50) | Turned profit | 3.82 | +79.1% |
| Net margin (%) | 11.5 | -1.4 | 7.7 |
Consolidated
- Filed with BSE
- 21 Jan 2026, 21:25 IST
- Board meeting
- 21 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 Jan 2026, 21:25 IST
- Board meeting
- 21 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE